Abstract
Introduction Overexpression of p16 has been reported in various human tumors. However, the correlation between p16 overexpression and the clinical pathological characteristics of cervical cancer remains contentious. Therefore, this meta-analysis aims to systematically evaluate the relationship between p16 expression and the clinical pathological features of cervical cancer.
Methods PubMed, Embase, Cochrane Library (Central), Web of Science (SCI Expanded), and Chine databases (CNKI, VIP, Wanfang, and CBM) were searched for relevant articles published between 1 January 2010 and March 01,2024. Case-control studies related to the correlation between p16 expression and cervical cancer were selected to evaluate the correlation between p16 expression and the clinicopathological features of cervical cancer patients. The software Review Man 5.4 was used for statistical and data processing, and heterogeneity tests and sensitivity analyses were performed. Literature quality was evaluated using the Newcastle-Ottawa scale. The software STATA 16.0 was selected for sensitivity analysis of the included studies, and publication bias was tested via Begg’s test.
Results Twenty-three eligible studies with, 1611 cervical cancer patients and 852 normal controls were included. p16 protein expression (cervical cancer patients VS normal controls) OR=74.32, 95%CI: 50.35-109.69, P<0.05; The expression of p16 protein in cervical cancer patients is associated with lymph node metastasis (metastatic lymph nodes vs. non-metastatic lymph nodes) OR=1.79, 95% CI: 1.29-2.47, P<0.05;The expression of p16 in patients with cervical cancer correlated with the degree of differentiation of the tumours (high and medium differentiation vs. low differentiation) (OR= 0.41, 95% CI: 0.30-0.56, P<0.05); the age of disease onset (age≤40 vs. age>40) (OR=0.55, Z=3.00, P=0.003<0.05), the status of choroidal infiltration in cervical cancer patients (yes vs. no) (OR=3.53, 95% CI: 1.25-10.01, P=0.02 <0.05), and tumour FIGO stage (stage I-II vs. stage III-IV) (OR=0.37, 95% CI: 0.18-0.76, P=0.0.007 <0.05), and these differences were statistically significant. p16 expression was not correlated with infiltration depth, tumour pathology type, tumour size, and these differences were not statistically significant.
Conclusion The p16 protein is closely related to the occurrence and development of cervical cancer and can serve as a reference indicator for the early warning and diagnosis of cervical cancer.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
